氨磷汀在接受化疗的老年恶性血液病患者中应用安全性的比较研究

目的评估氨磷汀在接受化疗的老年恶性血液病患者中应用的安全性。方法采用回顾性分析方法对年龄≥60岁（组1）和〈60岁（组2）的接受化疗的恶性血液病患者应用氨磷汀的副作用进行比较，了解在老年患者中应用的安全性。结果暂时性低血压为最常见的副作用，收缩压下降〉20mmHg在两组中发生率相当（分别为27．1％和28．8％，P〉0．05）。恶心和呕吐为第二大副作用，其发生率在组1中为10％，组2为20.8％（p〈0．05）。其它主观症状发生率两组相当。结论氨磷汀在接受化疗的老年恶性血液病患者中应用是安全的。无明显副作用。

Safety of amifostine in elderly hematologic malignancies patients receiv-ing chemotherapy: a comparative study

OBJECTIVE In order to evaluate the safety of amifostine in elderly hematologic malignancies patients receiving chemotherapy. METHODS The side effects of amifostine were compared in patients ≥60 years （group Ⅰ ） and patients 〈 60 years（group Ⅱ ） by retrospective study. RESULTS Transient hypotension was the most common side effect. Decreases in systolic blood pressure 〉20mmHg were of similar frequency in both groups （27.1% vs 28.8%, P 〉0.05）.Patients in group Ⅱ more often suffered from nausea/vomiting than in group Ⅰ （20.8% vs 10.0%, P 〈 0.05） .Other subjective groups.CONCLUSION Amifostine was administed symptoms occurred with similar frequency in both in elderly hematologic malignancies patients receiving chemotherapy was safety.